Therapeutic cancer vaccine using a recombinant gorilla adenoviral vector encoding HPV16/18 E6/E7 antigens; delivered subcutaneously to prime and expand HPV-specific CD8+ and CD4+ T cells by antigen presentation in dendritic cells.
Replication-deficient gorilla adenoviral vector delivers genes encoding HPV16/18 E6/E7 antigens to antigen-presenting cells, leading to intracellular expression and presentation on MHC I/II, priming and expanding HPV-specific CD8+ cytotoxic and CD4+ helper T cells and inducing antibody responses, which target and lyse HPV16/18 E6/E7–expressing tumor cells.
YES
INDIRECT
Vaccine primes HPV18 E6–specific CD8+ T cells; CTLs recognize E6-derived peptides on MHC I of tumor cells and kill via perforin/granzyme (and Fas–FasL) pathways.
Therapeutic cancer vaccine using a recombinant gorilla adenoviral vector encoding HPV16/18 E6/E7 antigens; delivered subcutaneously to prime and expand HPV-specific CD8+ and CD4+ T cells by antigen presentation in dendritic cells.
Replication-deficient gorilla adenoviral vector delivers genes encoding HPV16/18 E6/E7 antigens to antigen-presenting cells, leading to intracellular expression and presentation on MHC I/II, priming and expanding HPV-specific CD8+ cytotoxic and CD4+ helper T cells and inducing antibody responses, which target and lyse HPV16/18 E6/E7–expressing tumor cells.
YES
INDIRECT
Adenoviral vaccine primes HPV18 E7–specific CD8+ T cells; CTLs recognize E7 peptides on MHC I of tumor cells and kill them via perforin/granzyme-mediated cytolysis.
A bispecific T‑cell–engaging monoclonal antibody (REGN5458) that binds BCMA on plasma cells and CD3 on T cells to redirect cytotoxic T‑cell activity against BCMA-expressing plasma cells in MGUS/smoldering myeloma.
Linvoseltamab (REGN5458) is a bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells, bringing T cells into close proximity to BCMA+ cells to form an immune synapse. This triggers TCR/CD3-mediated T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxicity, selectively lysing BCMA‑expressing plasma cells.
YES
DIRECT
Bispecific BCMA×CD3 antibody redirects and activates T cells against BCMA+ cells, causing perforin/granzyme-mediated cytolysis (with cytokine release) of the target cells.
Anti-CD20×CD3 bispecific IgG T-cell–engaging antibody that links CD20 on B cells to CD3 on T cells to activate cytotoxic T cells and kill CD20+ B cells.
Bispecific anti-CD20xCD3 IgG antibody that binds CD20 on B cells and CD3 on T cells, redirecting and activating cytotoxic T cells to form an immune synapse and kill CD20-positive B cells.
YES
DIRECT
Bispecific antibody links CD20 on target B cells to CD3 on T cells, forming an immune synapse; activated T cells kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.
Anti-CD20×CD3 bispecific IgG T-cell–engaging antibody that links CD20 on B cells to CD3 on T cells to activate cytotoxic T cells and kill CD20+ B cells.
Bispecific anti-CD20xCD3 IgG antibody that binds CD20 on B cells and CD3 on T cells, redirecting and activating cytotoxic T cells to form an immune synapse and kill CD20-positive B cells.
NO
INDIRECT
Binds CD3 on T cells and CD20 on B cells to form an immune synapse, activating T cells to kill CD20+ B cells via perforin/granzyme-mediated cytotoxicity; CD3+ T cells are engaged, not killed.